One reason why RGS is price targetted at 77c/sh and 'outperform', page-10

Latest announcement is underwhelming to say the least. From a scientific / pipeline perspective it's ok -just- but from a comm / mktg perspective it's shameful... One lesson not learned from last year's AGM is: if your current shareholders are unhappy they are unlikely to recommend the company. Personally I'm very patient and invested heavily early on in RGS. I'm even optimistic long term regarding cancer vaccine. I agree that autologous stem cell treatments may not be the future (HiQCell is a bit invasive), however a good commercialisation strategy is to look at opportunities / niches markets and to deliver ad hoc strategies. RGS commercialisation strategy was sharper and clearer in the early days in Animal Health... then something happened and they lost their focus. Why? Anyway at $0.10 SP I'm a buyer.